IPM Insights

Pharmaceutical and biotechnology companies form alliances to accelerate new drug development and commercialization. These collaborations let companies share financial and operational risks while they leverage…

Product development alliances between global pharmaceutical giants and startup companies can be a win-win. They offer startups resources and reach, while larger entities gain access…

“How can we submit sooner?” It’s long been the most common question a regulatory submissions team hears. Executive leaders have ambitious goals in mind for…

It doesn’t matter how brilliant the researchers are or how many lives their potential new drug will save. Scientists can’t develop a new pharmaceutical on…

Drug discovery, development, and commercialization is like a puzzle. The end may be easy to visualize, but there are many pieces that need to be…

The product development timeline for a new pharmaceutical is fragile. If one link in the chain breaks, it delays everything else, including clinical trials, regulatory…

There’s an adage that says what gets measured gets improved. Regulatory submissions are no exception. And with the growing complexity of clinical trials and increasing…

The potential gains from digital pathology are endless. The ability to capture, curate, analyze, and rapidly share information about the effects of newly developed molecules…

Companies often begin achieving some business benefits of a merger or acquisition as soon as the two entities become one. And forward-looking organizations are eager…

Successful mergers and acquisitions integrations depend on strong leadership and a consistent message of a compelling shared vision and strategy. Presumably, a sound strategy drove…